Figures

2.1 'Hard' technological determinism and social determinism 8
2.2 Formal drug R&D process schematized by the linear model 21
3.1 Various β-blockers discussed in Chapter 3 40
3.2 Nifedipine and nicardipine (calcium antagonists) 55
4.1 Various β-stimulants discussed in Chapter 4 65
4.2 Various glucocorticoids discussed in Chapter 4 68
5.1 Various histamine H₂ antagonists and relevant chemicals 90
6.1 LHRH and its analogues discussed in Chapter 6 110
7.1 HMG-CoA reductase inhibitors discussed in Chapter 7 142
7.2 First generation cephalosporins and the 'active hydrogen' 151
7.3 Target compounds with the β-ketoacid side chain 152
7.4 The 'cyclization' of the β-ketoacid side chain resulting in formation of 2-aminothiazol-4-ylacetyl side chain 154
7.5 SCE-785 and cefotiam (cephalosporins) 155
7.6 Amosulalol (αβ-blocker) and tamsulosin (α₁c-blocker) 160
8.1 Interactions between the four aspects of drug shaping 184